Skip to content

Author

Yu Wang

We have 8 of 80 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

CD34+-selected stem cell boost for poor graft function after allogeneic hematopoietic stem cell transplantation: a large cohort study focusing on haploidentical transplantation.

CD34+-selected stem cell boost is safe and highly effective for refractory PGF after allo-HSCT, including in haploidentical recipients and those who have failed TPO-RAs.

Y. He, Lin-Wei Shi, R. Ma et al. · 0 citations
Open access Sep 2026

Haploidentical HSCT vs immunosuppressive therapy for severe aplastic anemia in patients aged 40-65 years: a retrospective comparative study

Abstract Severe aplastic anemia (SAA) is a life-threatening hematological disorder, and the optimal treatment for patients aged ≥40 years remains controversial. This retrospective study aims to conduct a comparative analysis of the efficacy of immunosuppressive therapy (IST) versus haploidentical hematopoietic stem cel...

Sheng-Quan Gao, Jin-Song Jia, Xiao-Jun Huang et al. · 0 citations
Review Open access Sep 2026

Age‐Stratified Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndromes: A Comprehensive Review

Myelodysplastic syndromes (MDS) are clonal disorders with high risk of progression to acute myeloid leukemia (AML). Allogeneic haematopoietic stem cell transplantation (allo‐HSCT), including haploidentical HSCT (haplo‐HSCT), is the only curative option. Age‐stratified selection of conditioning regimens based on organ r...

Ning Wu, Meng Lv, Xiao-Dong Mo et al. · 0 citations
Open access Sep 2026

Letermovir for cytomegalovirus prophylaxis after allogeneic hematopoietic stem cell transplantation in acute leukemia patients: results of the LETreal study

Objective Cytomegalovirus (CMV) infection can cause severe morbidity and mortality in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Letermovir is recommended as CMV prophylaxis for allo-HSCT recipients. This study aimed to further confirm the efficacy of letermovir prophylaxis in d...

Yi Xia, Qi Wen, Jing Liu et al. · 0 citations
Sep 2026

Ectopic EBV Infection in T Cells Identifies Reduced Therapeutic Responsiveness and Immune Dysfunction After Allogeneic Hematopoietic Stem Cell Transplantation.

OBJECTIVES EBV reactivation after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is typically monitored by plasma viral load, but this fails to capture cellular reservoirs. Lineage-specific testing, though usually performed in high-risk patients, may identify biologically distinct disease states. We aim...

Zhi-Fan Zhao, Zhuo-Jun Liu, Qiang Huang et al. · 0 citations
Open access Sep 2026

Single-cell mapping of thymus-dependent naïve t-cell regeneration reveals CD61-associated states after hematopoietic stem cell transplantation

This study defines cellular features of thymus-dependent naïve T-cell regeneration after HSCT and identifies CD61-associated naïve T-cell states as candidate peripheral features linked to thymic recovery and establishes a framework for evaluating peripheral signatures of thymic regeneration after HSCT.

Fangqing Zhang, Xinya Jiang, Shuang Fan et al. · 0 citations
Aug 2026

A novel conditioning regimen incorporating low-dose cyclophosphamide and thiotepa for haploidentical hematopoietic stem cell transplantation in pediatric patients with severe aplastic anemia at high risk of cardiotoxicity.

BACKGROUND High-dose cyclophosphamide (Cy)-related cardiotoxicity (CT) during transplant conditioning in patients with severe aplastic anemia (SAA) is a life-threatening complication. OBJECTIVE To evaluate the efficacy and safety of a modified conditioning regimen to reduce CT in pediatric SAA. METHODS We conducted...

Feng Zhang, P. Suo, Guan-Hua Hu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.